SRPT Q1 2025 Earnings — Sarepta Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

SRPTSarepta Therapeutics, Inc.

$2B

Q1 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$745M+80.2% YoY

Gross Profit

$607M81.5% margin

Operating Income

-$300M-40.3% margin

Net Income

-$448M-60.1% margin

EPS (Diluted)

$-4.60

QoQ Revenue Growth

+13.1%

Cash Flow

Operating Cash Flow

-$583M

Free Cash Flow

-$629M

Stock-Based Comp.

$41M

Balance Sheet

Total Assets

$3.5B

Total Liabilities

$2.3B

Stockholders' Equity

$1.1B

Cash & Equivalents

$241M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$745M	$413M	+80.2%
Gross Profit	$607M	$363M	+67.3%
Operating Income	-$300M	$35M	-960.6%
Net Income	-$448M	$36M	-1339.0%

Geographic Segments

UNITED STATES

$375M50%

Rest of World

$375M50%